Loading
companiesCompany
Nested Therapeutics
Nested Therapeutics hunts for hidden cancer-driving mutations and designs drugs to fit them. Its first drug, NST-628, sticks two signalling proteins (RAF and MEK) together to switch off a common cancer growth pathway.
Overview
Nested Therapeutics is a Cambridge, Massachusetts precision oncology company founded by Versant Ventures. Its platform maps mutational clusters onto protein structures to reveal cryptic driver mutations and druggable pockets, combining genomics, computational biophysics and machine learning. The lead programme, NST-628, is a non-degrading, brain-penetrant pan-RAF/MEK molecular glue that outperformed single agents and vertical combinations in RAS/MAPK-driven preclinical models; it is in a phase 1 study (NCT06326411) in adults with MAPK pathway-mutated or -dependent advanced solid tumours. A mutation-selective p53 pathway programme targets a cryptic pocket in a transcriptional regulator and has a lead compound. Nested launched in October 2022 with a 90 million US dollar Series A led by Goldman Sachs Asset Management, bringing total funding to 125 million US dollars.
Headquarters
Cambridge, MA, US
Funding
All startupsStartup
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by Goldman Sachs Asset Management; brought total financing to 125 million US dollars since Versant Ventures founded the company | 2022 | $90M | nestedtx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- No SEC Form D filings were found under the company name. The seed funding (35 million US dollars implied by the 125 million total) is not itemised in the release. Founding year not sourced.
Similar pages
- CompanyHarmonic Discovery
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
- CompanyReverie Labs
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
- IdeaExtend p53 reactivation beyond the Y220C mutation
Shares AI-driven drug & target discovery, TP53.
- PersonMaria E. Cabanillas
Shares BRAF, Small-molecule kinase inhibitors.
- PersonPaul Workman
Shares AI-driven drug & target discovery, Small-molecule kinase inhibitors.
- IdeaAn open degrader consortium against every undruggable driver transcription factor
Shares AI-driven drug & target discovery, TP53.
- PersonKeith T. Flaherty
Shares BRAF, Small-molecule kinase inhibitors.
- TrialCORRECT
Shares BRAF, Small-molecule kinase inhibitors.